Skip to main content
Close
Home
Society of Hospital Medicine
Presented by Society of Hospital Medicine
Home
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Richard Mark Kirkner

News

Healthy habits lower T2D microvascular risks: Cohort study

Author:
Richard Mark Kirkner
Publish date: January 31, 2023

A cohort study confirmed that adopting healthy habits before or after a diabetes diagnosis significantly lowered microvascular complication risks...

  • Read More

News

LDL cholesterol triglycerides ‘robust’ ASCVD risk marker

Author:
Richard Mark Kirkner
Publish date: January 10, 2023

A large dual-method Danish population study identified high LDL triglyceride levels as a risk marker for atherosclerotic cardiovascular disease....

  • Read More

News

Exacerbation history found flawed as COPD risk predictor

Author:
Richard Mark Kirkner
Publish date: January 5, 2023

Exacerbation history alone is not the most accurate risk-prediction tool.

  • Read More

News

DELIVER subanalysis ‘seals deal’ for dapagliflozin in HF

Author:
Richard Mark Kirkner
Publish date: December 15, 2022

An analysis of the large global DELIVER trial found that dapagliflozin improved outcomes and symptoms across a wide range of heart failure...

  • Read More

News

Seizures in dementia hasten decline and death

Author:
Richard Mark Kirkner
Publish date: December 14, 2022

Dementia patients who also had active seizures had shorter life expectancy and earlier decline than dementia patients who didn’t have active...

  • Read More

News

Three antiseizure medications join list for newborn risks

Author:
Richard Mark Kirkner
Publish date: December 13, 2022

A Scandinavian study of 4.5 million births adds carbamazepine, oxcarbazepine, and topiramate to list of antiseizure drugs linked to low birth...

  • Read More

News

Randomized trial finds DMARD therapy for RA has a beneficial effect on vascular inflammation, CV risk

Author:
Richard Mark Kirkner
Publish date: December 9, 2022

Receipt of a tumor necrosis factor inhibitor or triple therapy for rheumatoid arthritis yielded an equally beneficial effect for reducing vascular...

  • Read More

News

Study implicates myelin plasticity in absence seizures

Author:
Richard Mark Kirkner
Publish date: December 9, 2022

Researchers have found that changes in the insulating layer around nerves and axons in the brain may explain the progression of absence seizures...

  • Read More

News

Newer brand-name drugs fuel spending on antiseizure medications

Author:
Richard Mark Kirkner

Rapid adoption of newer antiseizure medications has pushed increases in government spending that outpace the growth of prescriptions themselves....

  • Read More

News

Novel PCI screening approach detects diffuse CAD

Author:
Richard Mark Kirkner
Publish date: December 7, 2022

Pullback pressure gradient pre-PCI can differentiate diffuse and focal coronary artery disease.

  • Read More

News

HDL cholesterol not linked to CHD risk in Blacks: REGARDS

Author:
Richard Mark Kirkner
Publish date: November 22, 2022

A large biracial cohort study found that low levels of high-density lipoprotein cholesterol don’t raise heart disease risk in Black patients.

  • Read More

News

ACR and EULAR roll out updated antiphospholipid syndrome criteria

Author:
Richard Mark Kirkner
Publish date: November 18, 2022

A joint planning group proposes updates to 16-year-old criteria for classifying antiphospholipid syndrome.

  • Read More

News

Denosumab may halt erosive hand OA progression

Author:
Richard Mark Kirkner
Publish date: November 17, 2022

In a randomized clinical trial, denosumab seemed to halt progression of erosive hand osteoarthritis, but had a delayed impact on pain.

  • Read More

News

StopRA trial: Hydroxychloroquine doesn’t prevent or delay onset of rheumatoid arthritis

Author:
Richard Mark Kirkner
Publish date: November 16, 2022

A randomized clinical trial found that hydroxychloroquine was no more effective than placebo at preventing or delaying onset of rheumatoid...

  • Read More

News

Combination therapy shows mixed results for scleroderma-related lung disease

Author:
Richard Mark Kirkner
Publish date: November 15, 2022

A study of mycophenolate mofetil alone and in combination with pirfenidone for scleroderma-related interstitial lung disease showed mixed results...

  • Read More

Pages

  • « first
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »
An Official Publication of the Society of Hospital Medicine

Society of Hospital Medicine
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Copyright  © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Menu Close